相关期刊:《World Journal of Clinical Cases》《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》《Journal of Geriatric Cardiology》《Chinese Journal of Traumatology》更多>>
Background The direct oral anticoagulant dabigatran does not require any routine therapeutic drug monitoring.Yet,concerns about possible drug interactions susceptible to increase its inherent bleeding risk,especially ...
supported financially by Boehringer Ingelheim Pharma GmbH&Co.KG
Background: Cerebral venous thrombosis (CVT) is a rare type of cerebrovascular disease associated with a 15% rate of death or function dependence. The mainstay of treatment for CVT is systemic anticoagulation, despite...
Objective: To review the literature for the emerging oral anticoagulants, dabigatran, rivaroxaban, and apixaban currently available in the United States. Data Source: A literature review was performed in MEDLINE (1947...